Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.

Sheba Medical Center and Israeli Medical Technology Company Nucleai Partner to Accelerate AI Powered Drug Discovery and Clinical Testing

Nucleai Partner
The new strategic partnership will help advance the use of AI-based solutions to aid in the discovery of histological biomarkers such as AI patient care and AI drug discovery and research.

Sheba Medical Center’s ARC Innovation Hub and Israeli medical technology company Nucleai have announced a new strategic data collaboration partnership for the purpose of increasing clinical trial efficacy and improving patient care through the use of AI.

Nucleai is a leading provider of AI-powered precision oncology platforms that leverage tissue datasets to produce insights that aid cancer biomarker analysis and treatment decisions. Nucleai’s software uses computer vision and machine learning algorithms to predict the progress of cancerous tumors as well as the patient’s immune system response based on a visual analysis of the tumor microenvironment.

This new partnership will see Nucleai gain access to millions of patient records provided by Sheba Medical Center, which will include pathology images, clinical data, genomics, and radiomics, along with other data modalities.

Sheba Medical Center and Nucleai have already partnered in the past to identify histological biomarkers that can predict the response of different cancer patients’ bodies to immunotherapy. This was done with the help of Sheba’s Institute of Pathology, a world leader in the field that acts as a center of diagnosis and research for precision medicine.

One success to come out of this previous collaboration, which was led by the Head of the Pathology Institute at Sheba, Prof. Iris Barshack, was a study that demonstrated the prediction efficiency of tumor microenvironment AI-based analysis for breast cancer. These findings were presented at the 2020 American Society of Clinical Oncology (ASCO) Conference.

In a statement released shortly after the announcement, Nucleai stated: “Through the combination of Nucleai and Sheba’s expertise across science, big data, and technology, we continue to transform and revolutionize the application of precision medicine across the healthcare ecosystem.”

Sheba Leverages ChatGPT
Accelerating Diagnostics: ChatGPT Results Aligned with Breast Cancer Board Recommendations
Recently, several distinguished Sheba clinicians were impressed by the tool’s capabilities. The group, which included Dr. Vera Sorin, Dr. Eyal Klang, Dr. Miri Sklair-Levy, Prof.…
Read More
Sheba and Vidac
Novel Drug Set to Improve CAR T-Cell Therapy Effectiveness
While many medical centers around the world depend on external labs to genetically engineer patient T-cells, a process that can take up to a few…
Read More
Sheba Named Global Oncology Leader
by Newsweek Magazine
Dedicated to providing those in need across the globe ‘Hope Without Boundaries,’ Sheba treats patients from more than 100 countries each year, employing the latest…
Read More